Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

BACKGROUND: Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negat...

Descripción completa

Detalles Bibliográficos
Autores principales: van ‘t Veer, Laura J., Yau, Christina, Yu, Nancy Y., Benz, Christopher C., Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Esserman, Laura J., Lindström, Linda Sofie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668340/
https://www.ncbi.nlm.nih.gov/pubmed/28776283
http://dx.doi.org/10.1007/s10549-017-4428-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668340/
https://www.ncbi.nlm.nih.gov/pubmed/28776283
http://dx.doi.org/10.1007/s10549-017-4428-9

Ejemplares similares